AWM
AXSM icon

Atticus Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Atticus Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15
Closed -$1.21K – 528
2024
Q2 		$1.21K Hold
15
– – ﹤0.01% 483
2024
Q1 		$1.2K Hold
15
– – ﹤0.01% 503
2023
Q4 		$1.19K Hold
15
– – ﹤0.01% 507
2023
Q3 		$1.05K Sell
15
-5
-25% -$374 ﹤0.01% 535
2023
Q2 		$1.44K Hold
20
– – ﹤0.01% 516
2023
Q1 		$1.23K Sell
20
-1,000
-98% -$65.7K ﹤0.01% 492
2022
Q4 		$78.7K Sell
1,020
-80
-7% -$4.78K 0.03% 202
2022
Q3 		$42K Hold
1,100
– – 0.02% 252
2022
Q2 		$42K Sell
1,100
-100
-8% -$3.16K 0.02% 274
2022
Q1 		$50K Buy
1,200
+300
+33% +$9.3K 0.02% 249
2021
Q4 		$34K Hold
900
– – 0.01% 268
2021
Q3 		$30K Buy
+900
New +$35.1K 0.01% 283

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atticus Wealth Management's AXSM Position: Q3 2024 in Review

Atticus Wealth Management sold out of Axsome Therapeutics (AXSM) in Q3 2024, closing a stake of 15 shares — an estimated $1.21K sold.

Atticus Wealth Management first reported a position in AXSM in Q3 2021 and held it in 12 quarters. The position peaked at $78.7K in Q4 2022. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Atticus Wealth Management reported no remaining Axsome Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Atticus Wealth Management sold 15 Axsome Therapeutics shares in Q3 2024, an estimated $1.21K.
  • Atticus Wealth Management first reported a position in Axsome Therapeutics in Q3 2021 and held it in 12 quarters.
  • Atticus Wealth Management's Axsome Therapeutics position peaked at $78.7K in Q4 2022.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Atticus Wealth Management's 13F filing for Q3 2024, filed 15 Oct 2024.